Geai 2010

Bienvenue

France
Suisse
Belgique
Luxembourg
Portugal
Algérie
Tunisie
Maroc


René-Louis Humbel
Chantal André
Alain Chevailler
Laurent Teste
Isabel Abreu
Sylvain Dubucquoi
Alain Chavailler
Pascale Chrétien
Andrée Escande
Nicole Fabien
Françoise Fortenfant
Joelle Goetz
Catherine Johanet
Jean-Claude Monier
Nils Olivier Olsson
Marielle Sanmarco
Jean Sibilia
Marie-France Taillefer


BIO advance
BIO-RAD
bmd
biomedical diagnostics
Biologie Prospective
BÜHLMANN
Phadia
2010
Merci
DiaSorin
eurobio
ORGENTEC
Werfen Group
Instrumentation Laboratory
MENARINI
France
MAST
L
A
B
LABODIA
InGen

SÉROLOGIE. — *Mise en évidence dans le sérum de malades atteints de Lupus erythémateux disséminé d'une substance déterminant une réaction de précipitation avec l'acide désoxyribonucléique.* Note de M. **Maxime Seligmann**,

SÉANCE DU 8 JUILLET 1957.

L'acide désoxyribonucléique (ADN) intervient dans les réactions de précipitation observées quand on met des extraits leucocytaires en présence du sérum de malades atteints de lupus erythémateux disséminé. Ces sérums réagissent avec des préparations d'ADN de différentes origines. La nature (anticorps ou histone ?) de cette substance sérique, absente du sérum humain normal, qui précipite avec l'ADN doit être discutée.



Maxime Seligmann
(14.03.1927 – 26.04.2010)

A DNA-Reacting Factor in Serum of a Patient with Lupus Erythematosus Diffusus.* (23544)

R. Ceppellini, E. Polli and F. Celada (Introduced by H. G. Kunkel)

Clinica Medica and Istituto Sieroterapico Milanese, Università di Milano and Institute for Study of Human Variations, Columbia University, N. Y.

13.09.1957

SÉROLOGIE. — *Mise en évidence dans le sérum de malades atteints de Lupus erythémateux disséminé d'une substance déterminant une réaction de précipitation avec l'acide désoxyribonucléique.* Note de M. **Maxime Seligmann**, présentée par M. Jacques Tréfouël.

08.07.1957



THE PRECIPITIN REACTION BETWEEN DNA AND A SERUM FACTOR IN SYSTEMIC LUPUS ERYTHEMATOSUS

By H. R. G. Deicher, M.D., H. R. Holman, M.D., and H. G. Kunkel, M.D.

(*From The Rockefeller Institute*)

(Received for publication, September 5, 1958)





AUTOANTICORPS

DIAGNOSTIC

CLASSIFICATION

PRONOSTIC

TRAITEMENT

AUTOANTICORPS PREDICTIFS

GAD - IA2	DIABETE INSULINODEPENDANT LADA
TPO	HYPOTHYROIDIE
PROTEINES CITRULLINEES	POLYATHRITE RHUMAT.
ONCONEURONAUX	TUMEUR CANCEREUSE

DIAGNOSTIC PRECOCE DE LA PR

SCORE DE LEIDEN 2007

Age du patient	**x 0.02**	**= points**
Sexe	**F**	**= 1 point**
Articulations touchées		
mains/pieds		**= 0.5 point**
symétriques		**= 0.5 point**
extrémités supérieures		**= 0.5 point**
sup. et inférieures		**= 0.5 point**
Raideur matinale (Sévérité - VAS)		
26 – 90 mm		**= 1.0 point**
> 90 mm		**= 2.0 points**
Nombres d'articulations douloureuses		
4 - 10		**0.5 point**
≥ - 11		**= 1.0 point**
Nombres d'articulations gonflées		
4 - 10		**= 0.5 point**
≥ - 11		**= 1.0 point**

CRP	**5 - 50 mg/l**	**= 0.5 point**
	> 50 mg/l	**= 1.5 points**
FR	**positif**	**= 1.0 point**
CCP	**positif**	**= 2.0 points**

Série t. FACULTÉ DE MÉDECINE ET DE PHARMACIE DE LYON N° 981

DE LA

NEUROMYÉLITE OPTIQUE AIGUË

THÈSE

PRÉSENTÉE

A LA FACULTÉ DE MÉDECINE ET DE PHARMACIE DE LYON

Et soutenue publiquement le 28 Novembre 1894

POUR OBTENIR LE GRADE DE DOCTEUR EN MÉDECINE

PAR

FERNAND GAULT

Né à Issy le 12 novembre 1871.

Ancien Externe des Hôpitaux de Lyon

Élève à l'École du Service de Santé Militaire

90.982

LYON

ALEXANDRE REY, IMPRIMEUR DE LA FACULTE DE MÉDECINE

4, RUE GENTIL, 4

Novembre 1894

1894







IgG ANTI - NMO

IF Cervelet

2004

ANTI – AQUAPORINE 4

IF Cellules Transfectées

2009

ANTI – AQUAPORINE 4

ELISA

2009

ENCEPHALITE LIMBIQUE

AUTO ANTICORPS

ANTI-CANAUX POTASSIQUES (VGKC)

ANTI- RECEPTEURS GLUTAMATE (NMADR)

ANTI-GLUTAMATE DECARBOXYLASE (GAD)

AUTOANTICORPS

1 CHOIX DES ANTICORPS A RECHERCHER

2. CHOIX DE LA METHODE

VALEUR CLINIQUE

SENSIBILITE

SPECIFICITE

FACILITE D'EXECUTION

QUELS AUTOANTICORPS RECHERCHER ?

LUPUS	150
POLYARTHRITE RHUMATOIDE	70
SCLERODERMIE	50
SCLEROSE EN PLAQUE	25
MAL. CROHN	15

MALADIE DE CROHN

ASCA	60 %
OmpC	40
OwpC	35
I2	30
Flagelline	50
Mannobioside	28
Laminaribioside	20
Chitobioside	21
Laminarine	26
Chitine	25
Pancréas Exocrine	40
GP2 , CUDZD	



INFORMER LE PRESCRIPTEUR

NOMENCLATURE DES AUTOANTICORPS

INTERPRETATION DES RESULTATS

GY 2010

ANTICORPS ANTI – NEUTROPHILE RECTOCOLITE HEMORRAGIQUE



ANCA

pANCA

aANCA

xANCA

GSANA

NANA

ANTI-CITRULLINATED PROTEIN / PEPTIDE ANTIBODIES

ACPAs

CPA	:	Filagrine de Rat recomb.Citrullinée	70 %
Anti-Sa	:	Vimentine Citrullinée (Wblot)	40 %
	:	MBP citrullinée (ELISA)	42 %
Anti-CCP2	:	Cyclic Citrullinated Peptide 2	85 %
Anti-CCP3	:	**Cyclic** Citrullinated Peptide 3	86 %
Anti-MCV	:	Mutated Citrullinated Vimentin	75 %

J Pediatr Gastroenterol Nutr. 2008 Oct;47(4):428-35.

Antigliadin immunoglobulin A best in finding celiac disease in children younger than 18 months of age.

Lagerqvist C, Dahlbom I, Hansson T, Jidell E, Juto P, Olcén P, Stenlund H, Hernell O, Ivarsson A.

Antigliadin antibody testing for coeliac disease in children under 3 years of age is unhelpful

S Holding,
M Abuzakouk,
P C Doré

J Clin Pathol ***2009;62:766767***

IMMUNOFLUORESCENCE



AUTOANTIBODIES DETECTED BY IMMUNOFLUORESCENCE

1957 - 1988 : 27

1957 : Nuclear
Thyroid
1959 : Cardiac Muscle
1961 : Granulocytes
1962 : Parietal Cells
Adrenal Glands
Steroid Cells
1964 : Epidermis (ICS)
Perinuclear Factor
ADN
1965 : Smooth-Muscle
Neurones
Mitochondria
1967 : Epidermis (BM)
1969 : Parathyroid
Glomerular BM

1971 : Reticulin
1973 : LKM
1974 : Pancreas (ICA)
1975 : Prolactin Cells
1979 : Keratin
1982 : ANCA
1985 : Endomysium
Myelin
1988 : LC1


CHRISTIAN FECHNER
VANESSA PARADIS
Elisa
UN FILM DE
JEAN BECKER
AVEC
GERARD DEPARDIEU

Luminex®


DOT ALLISON


ELISA
IFA
Nicole LACROIX


SSA
SCl70
U1RNP
SSB
Sm
RNAPol
JO1
PCNA
Fibril-
larine
PMScl
DNA
Mi2
RIBO P
CENPB

TESTS MULTIPARAMETRIQUES

MULTIPLEXAGE







ELISA IMMUNODOT BIOPUCES LUMINEX

PROFILS D'ANTICORPS

PROFILS DES ANTICORPS ANTI-GANGLIOSIDES

2007- Mars 2010 : 1699 Tests : 400 Positifs



IgG : 28 Profils Différents

IgM : 33 Profils Différents


COMPLEXE
Phosphatidyl-
serine
COMPLEXE
Cardiolipide
Phosphatidyl-
Choline
Prothrombine
ANTICORPS
ANTI-
PHOSPHOLIPIDES
β2 Glycoprotéine1
Annexine V
Phosphatidyl-
Ethanolamine
IgG / IgM

IMMUNOFLUORESCENCE



OVAIRE



TESTICULE



PLACENTA



HYPOPHYSE



ANTI-NUCLEOLAIRES

N = 55



n = 4

n = 8

n = 1

n = 2



Neg : 40

IMMUNODOT



ANTI – CELLULES DE PURKINJE

Yo

PCA2

PCA Tr



mGluR1

Ca

(ARHGAP26)

GluR2δ

Adenylate Kinase 5

Protein Kinase Cγ

HOMER 3

IMMUNOFLUORESCENCE

SUR CELLULES TRANSFECTEES

- SSA/Ro
- Aquaporine 4
- Recepteur MDAR du Glutamate
- Desmogléines 1 et 3
- BP 230
- PAgs Pancréas Exocrine

ANTI-RECEPTEUR GLUTAMATE NMDAR



CELLULES TRANSF..



CELLULES NON TRANSF.

IMMUNOESSAIS

ANTIGENES

NATIFS

COMPLEXES MACROMOLECULAIRES

Extraits Tissus ou Cellules

Origine Animale ou Humaine

RECOMBINANTS (Prokaryote)

(Eukaryote)

PEPTIDES SYNTHETIQUES

ANTICORPS ANTI – PR3

PROTEINASE 3
Native Humaine
Recombinante



ELISA

DIRECT



CAPTURE



ANCHOR



2010

AUTOANTICORPS



CUT - OFF
CUT - POINT

LIMITE
DOUTEUX
'BORDERLINE'
FAIBLEMENT POSITIF

Comparison of Threshold Cutpoints and Continuous Measures of Anti-Cyclic Citrullinated Peptide Antibodies in Predicting Future Rheumatoid Arthritis

LORI B. CHIBNIK, LISA A. MANDL, KAREN H. COSTENBADER, PETER H. SCHUR, and ELIZABETH W. KARLSON

Table 2. Relative risks and predictive accuracy of 5 threshold levels of anti-CCP level.

Level, U/ml	Anti-CCP+ Cases	Anti-CCP+ Controls	Odds Ratio Model 1* (95% CI)	Odds Ratio Model 2** (95% CI)	Sensitivity, %	Specificity, %
> 1	75 (81)	195 (72)	2.6 (1.3–5.5)	1.9 (0.9–4.3)	81	30
> 2	47 (51)	57 (20)	10.6 (4.8–23.0)	11.2 (4.7–26.9)	51	80
> 3	30 (32)	9 (3)	16.7 (6.5–43.3)	18.4 (6.5–52.4)	32	97
> 4	28 (30)	0 (0)			30	100
> 5	26 (28)	0 (0)			28	100

* Model 1: conditional logistic regression controlling for matching factors. ** Model 2: Model 1 with additional adjustment for residual age, body mass index (continuous), smoking status/pack-years of smoking categories (never, ever/< 11 pack-yrs, ever/≥ 11 pack-yrs), breastfeeding categories (nulliparous, parous/no breastfeeding, parous/< 1 yr breastfeeding, and parous/≥ 1 yr breastfeeding), menopause status/postmenopausal hormone use at diagnosis, menses before 12 years old, regularity of periods, and Caucasian race.

Conclusion. A lower threshold for anti-CCP positivity was more sensitive in predicting RA development. Higher ranges of the level were informative in predicting time to RA onset. (J Rheumatol First Release Feb 15 2009; doi:10.3899/jrheum.080895)

J.Rheumatol. 2009

Low Level (Below Cutoff) of Anti-Cyclic Citrullinated Peptide Test Results in Diagnosis of Rheumatoid Arthritis in a High-risk Population

Table 1. Diagnostic performance of 5 cut-off levels of anti-cyclic citrullinated peptide test for the diagnosis of rheumatoid arthritis.

	Level (U/ml)				
	> 1	> 2	> 3	> 4	> 5
Sensitivity (%)	91	86	83	82	80
Specificity (%)	46	68	74	78	82
PPV (%)	44	55	59	63	67
NPV (%)	91	91	91	90	90
PLR	1.69	2.71	3.20	3.74	4.35
NLR	4.88	4.78	4.45	4.26	4.10

PPV: positive predictive value, NPV: negative predictive value, PLR: positive likelihood ratio, NLR: negative likelihood ratio.

J.Rheumatol. 2010

DUCK-AN KIM, MD; THINK-YOU KIM, MD, Department of Early Arthritis/Laboratory Medicine, The Hospital for Rheumatic Diseases, Seoul, Republic of Korea. Address correspondence to Dr. T-Y. Kim, The Hospital for Rheumatic Diseases—Early Arthritis, Hanyang University Medical Center, 17 Haengdang-dong Seongdong-gu, Seoul 133-792, Republic of Korea. E-mail: tykim@hanyang.ac.kr

IDENTIFIER CORRECTEMENT LES AUTOANTICORPS



N'avancez rien qui ne puisse être prouvé de façon simple et décisive

STANDARDISATION DES METHODES

ANTICORPS POLYCLONAUX

ANTIGENES MULTIVALENTS



MATERIEL DE REFERENCE ?

ACCREDITATION

Au Secours

PREANALYTIQUE

PRELEVEMENT SANGUIN

TUBES EN VERRE
TUBES PLASTIQUES
TUBES GEL SEPARATEUR


Corrélation IgG (Tubes Gel)-IgG (Tubes Z)
IgG
IgG (Tubes Z)
IgG (Tubes Gel)
y = 0.92x + 91.6
r = 0.999
n = 34


Corrélation DNA (Tubes Gel)-DNA (Tubes Z)
DNA
DNA(Tubes Gel)
DNA (Tubes Gel)
y = 0.94x + 1.30
r = 0.99
n = 34


Corrélation RNP (Tubes Gel)-RNP (Tubes Z)
RNP
RNP (Tubes Z)
RNP (Tubes Gel)
y = 0.99x - 0.65
r = 0.999
n = 34


Corrélation SSA (Tubes Gel)-SSA (Tubes Z)
SSA
SSA (Tubes Z)
SSA (Tubes Gel)
y = 0.98x - 0.05
r = 1.00
n = 34


2010